JIA-HORNG KAOHO-HSIUNG LINPEI-JER CHENLai M.-Y.Wang T.-H.Mizokami M.DING-SHINN CHEN2021-03-032021-03-0319960944-1174https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984565340&doi=10.1007%2fBF02389521&partnerID=40&md5=53fb1a9763739782c4cf1835bac68fe5https://scholars.lib.ntu.edu.tw/handle/123456789/550273To evaluate the usefulness of a new serologic assay to group hepatitis C virus (HCV), genotypes identified by this serotyping method were compared to those identified by a polymerase chain reaction (PCR) assay with type-specific primers in 71 Taiwanese patients with chronic type C hepatitis. The group-specific antibodies against different HCV genotypes were detected by using an enzyme-linked immunosorbent assay (ELISA) based on group-specific recombinant peptides (C14-1 and C14-2) within the NS4 region. Among 71 patients positive for current second-generation HCV antibodies, HCV RNA was detected in 55 patients by PCR with primers from the 5' untranslating region, and in 52 by genotype-specific PCR. In 49 (89%) of 55 viremic patients, the results of serotyping by ELISA showed complete agreement with those determined by PCR genotyping, and none of the patients showed a group opposite to that of HCV genotype. The positive rate of group-specific antibodies (69/71; 97%) was even better than that of the PCR (55/71; 78%). We conclude that this new serotyping assay is highly sensitive and specific for the determination of HCV genotypes, and will be useful in future epidemiologic studies, as well for clinical application.[SDGs]SDG3hepatitis C antibody; virus RNA; adult; aged; article; chronic hepatitis; clinical trial; controlled clinical trial; controlled study; diagnostic value; enzyme linked immunosorbent assay; female; genotype; hepatitis C; Hepatitis C virus; human; intermethod comparison; major clinical study; male; polymerase chain reaction; priority journal; serotyping; Taiwanjournal article10.1007/BF0238952186805422-s2.0-84984565340